ABC Heart Fail Cardiomyop 2025; 5(1): e20250012
Reversal of Type 2 Pulmonary Hypertension after Levosimendan: A Challenging Approach Bringing New Insights
Helena Garcia Betinardi Bernardi
, Deborah de Sá Pereira Belfort
, Bruno Biselli
, Paulo Roberto Chizzola
, Robinson Tadeu Munhoz
, Silvia M. Ayub-Ferreira
, Edimar Alcides Bocchi
Abstract
Among the inotropic agents used in the management of heart failure, levosimendan, in particular, has a selective venodilator property that appears to explain its clinical benefit during pulmonary hypertension (PH). Most of the evidence refers to patients with group 2 PH and consequent right ventricular (RV) dysfunction. In this scenario, the observed benefits may be due to the effect of levosimendan on RV contractility and pulmonary vessel dilation, or to the improvement of left ventricular function and consequent reduction of pulmonary congestion. What we have noticed is that more and more studies are being done on this action and applicability of the drug, appearing in small studies, reviews and formal indications.
Keywords: Heart Failure; Heart Transplantation; Pulmonary Hypertension; Simendan
201
